Covid 19 resources
-
Maternal SARS-CoV-2, Placental Changes and Brain Injury in 2 Neonates
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Unique hepatic manifestations of COVID-19-induced immune dysregulation in children
Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff
Effect of Wearing a Face Mask on Hand-to-Face Contact by Children in a Simulated School Environment
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination
SARS CoV-2 detected in neonatal stool remote from maternal COVID-19 during pregnancy
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
‘Long COVID’: Symptom persistence in children hospitalised for COVID-19Analysis of COVID-19–Related Croup and SARS-CoV-2 Variant Predominance in the US
Association of SARS-CoV-2 Seropositivity and Symptomatic Reinfection in Children in Nicaragua
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
In-person schooling and associated COVID-19 risk in the United States over spring semester 2021- Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students
- A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland
- Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2—A Report From the US National COVID Cohort Collaborative
- Intrinsic Severity of SARS-CoV-2 Omicron BA.2 in Uninfected, Unvaccinated Children: A Population-Based, Case-Control Study on Hospital Complications
- Effects of SARS-CoV-2 on prenatal lung growth assessed by fetal MRI
- Global, regional, and national minimum estimates of children affected by COVID-19-associated orphanhood and caregiver death, by age and family circumstance up to Oct 31, 2021: an updated modelling study
- Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021
- Model-Estimated Association Between Simulated US Elementary School–Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels
- Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022
Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection - Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications
- Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative
- Association of Child Masking With COVID-19–Related Closures in US Childcare Programs
- Covid-19: Omicron variant is linked to steep rise in hospital admissions of very young children
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
- Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection
- Feasibility of SARS-CoV-2 Surveillance Testing Among Children and Childcare Workers at German Day Care Centers
- Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 years — United States, March 1, 2020–June 28, 2021
- Safety data from vaccination of children 5-11 years (CDC)
- Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection
- Multisystem Inflammatory Syndrome in Children by COVID-19 Vaccination Status of Adolescents in France
- Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy
Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada - ACIP slides on vaccination of children
- Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization — United States, March 2020–September 2021
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
- A need of COVID19 vaccination for children aged <12 years: Comparative evidence from the clinical characteristics in patients during a recent Delta surge (B.1.617.2)
- Pediatric COVID-19 Vaccines- What Parents, Practitioners, and Policy Makers Need to Know
- Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage
- Hospitalisation rates by age in Australia
- Transmission of SARS-CoV-2 After COVID-19 Screening and Mitigation Measures for Primary School Children Attending School in Liège, Belgium
- Age-Specific Changes in Virulence Associated with SARS-CoV-2 Variants of Concern
- Pediatric COVID-19 Cases in Counties With and Without School Mask Requirements — United States, July 1–September 4, 2021
- Assessment of a Program for SARS-CoV-2 Screening and Environmental Monitoring in an Urban Public School District
- Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum
- Predictors of Nonseroconversion after SARS-CoV-2 Infection
- American Academy of Pediatrics data on Delta in Children
- Strategies to minimize SARS-CoV-2 transmission in classroom settings: combined impacts of ventilation and mask effective filtration efficiency
- Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021
- Short-term Reactions Among Pregnant and Lactating Individuals in the First Wave of the COVID-19 Vaccine Rollout
CDC guidelines for schools - Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021
- SARS-CoV-2 aerosol transmission in schools: the effectiveness of different interventions
- Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity
- Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children
- Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection
- SARS-CoV-2 Infection Among Maternal-Infant Dyads in Ontario, Canada
- Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2
- Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020
- Household Transmission of SARS-CoV-2 from Children and Adolescents
- Long COVID and kids: scientists race to find answers
- The vaccine endgame and why children matter
- Universal Screening for SARS-CoV-2 in Women Admitted for Delivery
- Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children
- Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges
- SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020
- Infectivity of severe acute respiratory syndrome coronavirus 2 in children compared with adults
- COVID-19 in children and the effect of schools reopening on potential transmission to household members
- In-Hospital Mortality in a Cohort of Hospitalized Pregnant and Nonpregnant Patients With COVID-19
- Clinical Characteristics and Transmission of COVID-19 in Children and Youths During 3 Waves of Outbreaks in Hong Kong
- Reasons for Admissions to US Children’s Hospitals During the COVID-19 Pandemic
- Association of Maternal SARS-CoV-2 Infection in Pregnancy With Neonatal Outcomes
- Outbreak in schools after opening of schools, Israel
- Children with MIS-C
- Infection in contacts of children aged year K-12
- Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic
- Children and SARS CoV 2
- Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19)
- American academy of pediatrics data on child COVID-19 cases
- Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020
- Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea
- Household secondary attack rate highest when index case is a child
- SARS-CoV-2 in cardiac tissue of a child
- Role of children in household transmission
- Study showing higher viral shedding in children <5 years
- School cluster of COVID-19 in France
- SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission
- Good summary of schools, children and COVID-19
- Multisystem inflammatory disease in children
- Renal disease in children
- Outcomes in pregnant women
- Kawasaki disease US
- Kawasaki disease in the UK
- Kawasaki diseases in France
- Lower ACE2 receptor expression in children<10 years compared to people >10 years
- 2005 study showing association of coronaviruses with Kawasaki disease
- SARS CoV 2 viral loads in children vs adults
- NEJM COVID in children
- Paediatric cases in the USA
- Persistent viral shedding in children (Nature Medicine)
- Epidemiology in children (review)
- SARS-COV2 in Children. NEJM 2020
- Detection of COVID in febrile children in January in Wuhan
- Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China.
- A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features.
- A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet.
- Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China." JAMA.
- Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records." Lancet.
- Asymptomatic children can shed virus for 10 days or more. Lancet.
- JAMA: neonatal COVID 19
- SARSCoV2 in childen
- Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study
- Lay summary of risk of transmission in kids
-
- Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study
- Detection of viable SARS-CoV-2 in retrospective analysis of aerosol samples collected from hospital rooms of patients with COVID-19
- Quantification of Infectious SARS-CoV-2 by the 50% Tissue Culture Infectious Dose Endpoint Dilution Assay
- Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains
- SARS-CoV-2 viral load and shedding kinetics
- COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods
- Impact of Age and Symptom Development on SARS-CoV-2 Transmission in Households With Children—Maryland, New York, and Utah, August 2020–October 2021
- Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains
- Monitoring SARS-CoV-2 in air and on surfaces and estimating infection risk in buildings and buses on a university campus
- SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022
- Low rate of transmission to triple-vaccinated contacts of an imported case of SARS-CoV-2 omicron infection: A contact tracing study in Israel
- SARS-CoV-2 Omicron VOC Transmission in Danish Households
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Orthodoxy, illusio, and playing the scientific game: a Bourdieusian analysis of infection control science in the COVID-19 pandemic
- Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection
- Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted by COVID-19 Patients while Breathing, Talking, and Singing
- Aerosol Dynamics Model for Estimating the Risk from Short-Range Airborne Transmission and Inhalation of Expiratory Droplets of SARS-CoV-2
- How Did We Get Here: What Are Droplets and Aerosols and How Far Do They Go? A Historical Perspective on the Transmission of Respiratory Infectious Diseases
- Transmissibility and transmission of respiratory viruses
- Viral load and super-spreading
- Attack rate in Manaus, Brazil
- Increased transmissibility of B117 variant in the UK
- Transmissibility of B117 variant
- Age-dependent effects in the transmission and control of COVID-19 epidemics
- Household attack rates in the US
- Epidemiology and transmission dynamics in 2 Indian states (large contact tracing study)
- Secondary household attack rates - metaanalysis
- Data from 3 outbreak clusters with presymptomatic transmission
- 85% attack rate on a fishing trawler
- Household contact study from the US
- Transmission on a train
- Airborne transmission as the dominant mode
- Projecting the transmission dynamics of SARS CoV 2 through the post-pandemic period
- High transmission near symptom onset
- Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia." New England Journal of Medicine.
- A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster." The Lancet.
- Secondary attack rate and superspreading events for SARS-CoV-2." Lancet.
- The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application
- Retracted study (reasons unknown) showed transmission of COVID19 over 4.5m on a bus https://www.scmp.com/news/china/science/article/3074351/coronavirus-can-travel-twice-far-official-safe-distance-and-stay
- COVID can survive in the air for 3 hours
- Estimating the generation interval for COVID-19 based on symptom onset data.
- Prof Don Milton on WHO statement that COVID-19 is not airborne
- Transmission at a bath centre in China
- Droplets generated through normal speech
- Coronaviruses exhaled in normal breathing, prevented by a mask
-
Association of SARS-CoV-2 infection and persistence with long COVID
Persistent COVID-19 symptoms in a community study of 606,434 people in England
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
Cognitive impairment in young adults with post COVID-19 syndrome
High risk of autoimmune diseases after COVID-19Lower prevalence of Post-Covid-19 Condition following Omicron SARS-CoV-2 infection.
Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study
Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort StudyAssociation of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition
Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study
Longitudinal Assessment of Chest CT Findings and Pulmonary Function in Patients after COVID-19
Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19
Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic
Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infectionSARS-CoV-2 infection and persistence in the human body and brain at autopsy
Report on Long COVID Urges Actions to Address Needs of Patients, CaregiversEnhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids
Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution
Acute and postacute sequelae associated with SARS-CoV-2 reinfection
Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19
Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19
Prevalence and Correlates of Long COVID Symptoms Among US Adults
Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study
- Transcriptomic profiling of cardiac tissues from SARS-CoV-2 patients identifies DNA damage
- Long-term neurologic outcomes of COVID-19
Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study - Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China
- Pulmonary function and chest computed tomography abnormalities 6–12 months after recovery from COVID-19: a systematic review and meta-analysis
- Larger gray matter volumes in neuropsychiatric long-COVID syndrome
- Long-term cardiac pathology in individuals with mild initial COVID-19 illness
- A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
- Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers
- Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients
- Distinguishing features of Long COVID identified through immune profiling
- Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2–induced lung exudative vasculitis and predicts COVID-19 severity
- Symptoms and risk factors for long COVID in non-hospitalized adults
- Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers
- Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records
- Long COVID symptoms in SARS-CoV-2-positive children aged 0–14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study
- Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2
- “Long COVID” results after hospitalization for SARS-CoV-2 infection
- Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases
- Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection
- Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021
- CORona (COVID-19) Follow Up Study: Epidemiology, Pathophysiology, Prediction, and Communication (CORFU)
- Clues to long COVID
-
- Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
- Robust T cell responses to Pfizer/BioNTech vaccine compared to infection and evidence of attenuated peripheral CD8+ T cell responses due to COVID-19
- SARS-CoV-2 variant biology: immune escape, transmission and fitness
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster - Strong attenuation of SARS-CoV-2 Omicron BA.1 and increased replication of the BA.5 subvariant in human cardiomyocytes
- Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
- Persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium
SARS-CoV-2 viral load and shedding kinetics - SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
- SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
- Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
- Acute and postacute sequelae associated with SARS-CoV-2 reinfection
- COVID-19 primary series and booster vaccination and immune imprinting
- Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
- Prevalence of Positive Rapid Antigen Tests After 7-Day Isolation Following SARS-CoV-2 Infection in College Athletes During Omicron Variant Predominance
- Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
- Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark
- Impaired immune response drives age-dependent severity of COVID-19
- Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
- SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry
- Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
- Larger gray matter volumes in neuropsychiatric long-COVID syndrome
- Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study
- Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant–Infected Vaccinees
- Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland
- Duration of Symptoms and Association With Positive Home Rapid Antigen Test Results After Infection With SARS-CoV-2
- SARS-CoV-2 is detected in the gastrointestinal tract of asymptomatic endoscopy patients but is unlikely to pose a significant risk to healthcare personnel
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection - Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
- Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals
- Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
- ACE2-independent infection of T lymphocytes by SARS-CoV-2
- Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2—A Report From the US National COVID Cohort Collaborative
- Herd immunity by infection does not work - SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
- Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
- Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
- A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
- Omicron infection enhances neutralizing immunity against the Delta variant
- Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection
- Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain
- Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa
- Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
- The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
- Transmission dynamics and epidemiological characteristics of Delta variant infections in China
- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
- Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
- Predictors of Nonseroconversion after SARS-CoV-2 Infection
- Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children
- Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
- Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection
- Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols
- Estimating infectiousness throughout SARS-CoV-2 infection course
- Variants, transmissibility and variants B117, B1351 and P1
- Pathophysiology of COVID-19
- Reinfection, Brazil
- Reinfection risk after 6 months
- Prolonged shedding of B117
- Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
- Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events
- Summary of variant strains and vaccine escape potential
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- Antibody dependent enhancement
- Novel ACE Isoform
- Antibody responses to SARS CoV 2 infection (IgA, IgM)
- Anti-phospholipid antibodies and thormbosis
- Will SARS CoV 2 become endemic (Science)
- Reinfection with SARS CoV 2
- Ultra-potent human antibodies to SARS CoV 2
- Loss of SARS CoV 2 antibodies in mild infection
- Antibody-like proteins that capture and neutralize SARS-CoV-2
- Antibody Profiles and Mild or Severe SARS-CoV-2
- Differential Tropism of SARS-CoVs in Bat Cells
- SARS-CoV-2 in Quarantined Domestic Cats from COVID-19 Households or Close Contacts, Hong Kong, China
- Short term immunity from seasonal coronaviruses
- Neurological complications
- Neuroinvasion
- Viral shedding in severe and mild cases
- Long duration of viral shedding
- Cardiac pathology in COVID-19
- Reinfection with more severe infection the second time
- A case of reinfection in Hong Kong
- How long should isolation be - review of viral shedding data
- Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
- ACE2 expression in resp tract of adults, children, patients with COPD
- Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
- Cases who re-test positive after discharge - data from S Korea suggest not infectious
- Infection gradient in the respiratory tract (Cell)
- Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
- Viable virus in faeces
- Reinfection with seasonal coronaviruses
- Proportion of test positive cases in Seattle and Washington State EDs and outpatient clinics
- Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study
- Virological assessment of hospitalized patients with COVID-2019 (Nature)
- SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. New England Journal of Medicine. (contains data on asymptomatic shedding)
- Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA.
- Fecal Specimen Diagnosis 2019 Novel Coronavirus-Infected Pneumonia.
- Study in macaques on reinfection
- Low levels of antibodies in recovered patients
- Viral shedding in upper and lower respiratory tract
- immune dysfunction in covid19
- Reinfection
-
- Outbreak Reports: An Outbreak of SARS-CoV-2 Omicron Subvariant BA.2.76 in an Outdoor Park — Chongqing Municipality, China, August 2022
- Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity
- Examination of SARS-CoV-2 In-Class Transmission at a Large Urban University With Public Health Mandates Using Epidemiological and Genomic Methodology
- Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
- Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis
- SARS-CoV-2 Omicron VOC Transmission in Danish Households
- An upper bound on one-to-one exposure to infectious human respiratory particles
- Airborne transmission of SARS-CoV-2 over distances greater than two metres: a rapid systematic review
- Airborne transmission of respiratory viruses
- Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis PNAS 2021
- Household secondary attack rates
- How did we get here: what are droplets and aerosols and how far do they go? A historical perspective on the transmission of respiratory infectious diseases
- Airborne transmission in a church, Australia
- Seropositivity in household contacts
- Rates of asymptomatic infection in the US
- Transmission from asymptomatic people
- Viral load in asymptomatic higher than symptomatic
- Transmission risk in outdoor and indoor settings
- Mass screening in Wuhan and asymptomatic infection
- OUtbreak data on proportion symptomatic and asymptomatic
- Long distance spread of SARS CoV 2 in a hospital
- Aerosol transmission between ferrets
- Clinical and immunological features of asymptomatic infection
- Modelling of Diamond Princess outbreak shows 69% of transmission was from asymptomatic
- Half of infections on cruise ship were asymptomatic
- Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea
- Prevalence of asymptomatic infection - review (Annals Int Med)
- Contact infection rate
- Asymptomatic and presymptomatic transmission in an outbreak in Germany (Lancet)
- Asymptomatic infection on the Diamond Princess
- Natural history of asymptomatic infection (NEJM)
- Summary of different studies showing high rates of asymptomatic infection
- Up to 44% infections occur when index case is presymptomatic (Nature)
- Asymptomatic infection in aged care (CDC)
- Asymptomatic infection in aged care (NEJM)
- Asymptomatic infection - population screening in Iceland
- Relative transmissibility of asymptomatic cases
- "The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights."
- Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China.
- Presumed Asymptomatic Carrier Transmission of COVID-19." JAMA
- Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany New England Journal of Medicine.
- Asymptomatic Novel Coronavirus Pneumonia Patient Outside Wuhan: The Value of CT Images in the Course of the Disease
- 2019-nCoV transmission through the ocular surface must not be ignored
- Estimating the Asymptomatic Proportion of 2019 Novel Coronavirus onboard the Princess Cruises Ship, 2020
- Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020
- SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. New England Journal of Medicine. (contains data on asymptomatic shedding)
- Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020
- Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission clusteral
- Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science 16 Mar 2020:
- Transmission in aircraft
- Why testing matters - the case study of USA
- Summary of evidence on infectious period
- Use of masks for sick patients - human coronaviruses
- SARS-CoV-2 in blood donations
- Barrier box for endotracheal intubation (NEJM)
- Transmission from deceased patients in a morgue
- Substantial undocumented transmission of SARS CoV 2
- Airborne transmission of SARSCoV 2
- Comparative aerosol efficiency of SARS, SARS COV2 and MERS COV
-
- Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023
- High risk of autoimmune diseases after COVID-19
- Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022-2023
- Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland
- Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic
- Risk of incident heart failure after COVID-19 recovery: a systematic review and meta-analysis
- Impact of SARS-CoV-2 variants on inpatient clinical outcome
- SARS-CoV-2 infection and persistence in the human body and brain at autopsy
- Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis
- COVID-19 and Excess All-Cause Mortality in the US and 20 Comparison Countries, June 2021-March 2022
- Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults
A Systematic Review and Meta-analysis - Seeing Blue Dots After COVID-19 Infection
- COVID-19 and Excess All-Cause Mortality in the US and 20 Comparison Countries, June 2021-March 2022
- Enhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids
- Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England
- Life expectancy changes since COVID-19
- Transcriptomic profiling of cardiac tissues from SARS-CoV-2 patients identifies DNA damage
- Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose
- IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination
- Association of COVID-19 with New-Onset Alzheimer’s Disease
- Laboratory-Confirmed COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance — COVID-19–Associated Hospitalization Surveillance Network, 14 States, June 20, 2021–May 31, 2022
- Larger gray matter volumes in neuropsychiatric long-COVID syndrome
- Long-term cardiac pathology in individuals with mild initial COVID-19 illness
- COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status
- Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients
- Understanding COVID-19-associated coagulopathy
- SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19
- Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection
- Symptoms and risk factors for long COVID in non-hospitalized adults
- Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK
- Excess Mortality in Massachusetts During the Delta and Omicron Waves of COVID-19
- Neurovascular injury with complement activation and inflammation in COVID-19
- Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings
“Long COVID” results after hospitalization for SARS-CoV-2 infection
Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation
SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19
- Long COVID after breakthrough SARS-CoV-2 infection
- Excess Mortality in Massachusetts During the Delta and Omicron Waves of COVID-19
- Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort
- Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study
Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates - Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022
Global and National Declines in Life Expectancy: An End-of-2021 Assessment - Even Mild COVID-19 May Change the Brain
- Risks and burdens of incident diabetes in long COVID: a cohort study
- Asystole in a COVID-19 patient without systemic illness: a case report
- One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China
A Longitudinal Cohort Study - Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21
- SARS-CoV-2 is associated with changes in brain structure in UK Biobank
- Endothelial dysfunction in acute and long standing COVID−19: A prospective cohort study
- Molecular imaging findings on acute and long-term effects of COVID-19 on the brain: A systematic review
- Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae
- Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
- Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19
- Long-term cardiovascular outcomes of COVID-19
- Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant
- SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer's-like neuropathology
- SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022
- Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022
- Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition,mild cognitive impairment,or Alzheimer’s dementia
- Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa - Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain
- Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves
- Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors
- SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature
Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves - SARS-CoV-2 infection and persistence throughout the human body and brain
- 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records
- Hospitalisation risk for Omicron cases in England
- Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
- Leading Causes of Death Among Adults Aged 25 to 44 Years by Race and Ethnicity in Texas During the COVID-19 Pandemic, March to December 2020
- Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
- Do vaccines protect against long COVID? What the data say
- COVID and the brain: researchers zero in on how damage occurs
- Effect of COVID-19 vaccination on menstrual periods in a retrospectively recruited cohort
- Cardiac injury in COVID‑19
- Uncertainty around the Long-Term Implications of COVID-19
- Anti–SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms
- Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer
- Association Between COVID-19 Diagnosis and In-Hospital Mortality in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction
- Assessment of Cognitive Function in Patients After COVID-19 Infection
- The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells
- Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection - A Systematic Review
- Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19
- Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China
- Cognitive deficits in people who have recovered from COVID-19
- Platelets amplify endotheliopathy in COVID-19
- COVID-19 Case Age Distribution: Correction for Differential Testing by Age
- SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
- Brain imaging before and after COVID-19 in UK Biobank
- Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
- Clinical and Virological Features of SARS-CoV-2 Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta)
- High-dimensional characterization of post-acute sequelae of COVID-19
- Long COVID - largest case series
- Infection fatality rate by age
- Risk of death from B117
- Impact of COVID-19 restrictions on traffic accidents and injuries
- Risk of mortality for B117 variant
- Severe COVID-19 pneumonia
- Impact of COVID measures on other viruses
- Impact of COVID measures on influenza
- Risk of death in teachers
- All cause deaths in the US during 2020
- Effect of school closures in the US
- Sequelae in Adults at 6 Months After COVID-19 Infection
- Comparison of hospitalised influenza and COVID-19
- Readmission in death in survivors
- Varying severity of disease in identical twins
- Lower risk of COVID in people with asthma
- Evidence of SARS CoV 2 in the US in December 2019
- Post-acute complications
- COVID-19 and cardiac arrest
- Risk factors for COVID-19 - meta-analysis. Hypertension, CVD, COPD, diabetes
- Incidence and treatment of arrhythmias secondary to coronavirus infection in humans
- Chronic manifestations of COVID-19
- Risk factors in US veterans - ethnicity not a risk factor
- COVID-19 and the heart
- Eye glasses and risk of COVID
- Risk factors for COVID-19 severe outcomes
- Clinical presentations of COVID patients
- Post-mortem findings (JAMA)
- Diffuse pulmonary arterial thrombosis in fatal cases
- Large vessel stroke in younger adults, some without symptoms of COVID-19 (NEJM)
- Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
- Estimating Risk for Death from 2019 Novel Coronavirus Disease, China, January–February 2020.
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.
- The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA.
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study." Lancet.
- Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine.
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China." Lancet.
- First Case of 2019 Novel Coronavirus in the United States. New England Journal of Medicine.
- Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore." JAMA.
- The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. China CDC Weekly, 2020, 2(8): 113-122
- Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China.
- Case series from Seattle, NEJM
- Coronavirus: Why it’s so deadly in Italy
- Case fatality 7.2% in Italy - JAMA
- Patients dying in Italy
- Cross country CFR comparision
- CFR in Germany and European countries
- Epidemiology in the US
- Who has flattened the curve best?
- Estimates of the severity of coronavirus disease 2019: a model-based analysis (Lancet)
- Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 (NEJM)
- Olfactory epithelium and anosmia
- Immune thrombocytopenia
- Outbreaks in detention centres
- Guillaine Barre Syndrome associated with SARS CoV 2 infection
- Complex immune dysregulation (Cell)
- Neurological complications
- Does MTB increase the risk of COVID19?
- Antibody dependent immune enhancement with COVID19
-
- Pre-Existing Population Immunity and severe acute respiratory syndrome coronavirus 2 Variant Establishment and Dominance Dynamics in the United States: An Ecological Study
- Modeling transmission of SARS-CoV-2 Omicron in China
- Relative Instantaneous Reproduction Number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark
- The Incubation Period Distribution of Coronavirus Disease 2019: A Systematic Review and Meta-analysis
- Delta’s rise is fuelled by rampant spread from people who feel fine
- Transmission dynamics and epidemiological characteristics of Delta variant infections in China
- The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus
- The economic burden of COVID-19 in the United States: Estimates and projections under an infection-based herd immunity approach
- Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
- Manaus, Brazil - reinfection with P1
- Infectiousness of B117 variant in the UK
- Super-spreading and R0 estimates in Indonesia
- Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study." Lancet
- Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia." New England Journal of Medicine.
- How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet.
- Identifying Locations with Possible Undetected Imported Severe Acute Respiratory Syndrome Coronavirus 2 Cases by Using Importation Predictions. EID
-
- Pulmonary function and chest computed tomography abnormalities 6–12 months after recovery from COVID-19: a systematic review and meta-analysis
- Concordance of SARS-CoV-2 Results in Self-collected Nasal Swabs vs Swabs Collected by Health Care Workers in Children and Adolescents
- Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2–induced lung exudative vasculitis and predicts COVID-19 severity
- False-Positive Results in Rapid Antigen Tests for SARS-CoV-2
- Rapid Diagnostic Testing for SARS-CoV-2
- False-Positive Results in Rapid Antigen Tests for SARS-CoV-2
- Interpreting a covid-19 test result
- Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series
- Saliva swabs are the preferred sample for Omicron detection
- The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity
- Interpreting SARS-CoV-2 Test Results
- Assessment of Simulated Surveillance Testing and Quarantine in a SARS-CoV-2–Vaccinated Population of Students on a University Campus
- Validation of an At-Home Direct Antigen Rapid Test for COVID-19
- Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection
- Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates
- The fuss about cycle threshholds for PCR
- Salivary test
- Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure
- Performance of self-collected nasal swabs
- Detection of SARS-CoV-2 in Different Types of Clinical Specimens JAMA.
- Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing.
- Asymptomatic Novel Coronavirus Pneumonia Patient Outside Wuhan: The Value of CT Images in the Course of the Disease
- Molecular diagnostics and antibody tests
- Serological responses (IgM and IgG) to COVID 19
- Neutralizing antibody response in recovered patients
- Antibody responses
- Lower antibodies in asymptomatic infected
- Use of salivary testing
- Immunological correlates of protection
- Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients
-
- Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19
- Bergamo, Italy
- Wuhan, China
- United states - asymptomatic seropositive rates
- Vo, Italy
- Santa Clara County, California, USA
- Iceland
- Los Angeles, USA
- Bergamo, Italy
- Geneva, Switzerland
- Spain
- United States blood donors
- Elective surgery patients, Australia
- Karnataka, India
- South Korea
-
- Longitudinal dynamics of Streptococcus pneumoniae carriage and SARS-CoV-2 infection in households with children
- Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome
- Early Bacterial Identification Among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Cohort Study
- Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU
- Bloodstream infections in critically ill patients with COVID-19
- Co-infection with respiratory pathogens among COVID-2019 cases
- Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract
- Bacterial co-infections and antibiotic resistance in patients with COVID-19
- Streptococcus pneumoniae coinfection in hospitalised patients with COVID-19
- Pneumococcal carriage in children with COVID-19
- SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections
- Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England
- A Retrospective Study of Coinfection of SARS-CoV-2 and Streptococcus pneumoniae in 11 Hospitalized Patients with Severe COVID-19 Pneumonia at a Single Center
- Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y León, Spain
- Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV
- Lung Pathology of Mutually Exclusive Co-infection with SARS-CoV-2 and Streptococcus pneumoniae
- Community-acquired bacteraemia in COVID-19 in comparison to influenza A and influenza B: a retrospective cohort study
- High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections
- Co-infection in critically ill patients with COVID-19: an observational cohort study from England
- Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: An observational study
- Bacterial coinfections in coronavirus disease 2019
- Invasive pneumococcal disease affected the fatal outcome in a COVID-19 patient
- Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data
- Respiratory bacterial co-infections in intensive care unit-hospitalized COVID-19 patients: Conventional culture vs BioFire FilmArray pneumonia Plus panel
- Prevalence of Bloodstream Infections and their Etiology in COVID-19 Patients Admitted in a Tertiary Care Hospital in Jaipur
- Co-infection in Australia
- Increased risk of death with influenza/SARS CoV 2 infection
- Co-infection (JAMA)
- Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan.
- Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. EID
- 20% rate of co-infection (JAMA)
-
- Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
- Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation
- Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2 - SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 34
- Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant
- Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- EVOLVING THREAT: New variants have changed the face of the pandemic. What will the virus do next?
- The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry.
- SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- SARS-CoV-2 infection and persistence throughout the human body and brain
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain
- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
SARS-CoV-2 reinfection trends in South Africa: analysis of routine surveillance data - Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
- Comment on “Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2” (infectious dose)
- SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
- The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
- The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells
- The continuous evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations of concern and global detection
- Transmission dynamics and epidemiological characteristics of Delta variant infections in China
- The unique evolutionary dynamics of the SARS-CoV-2 Delta variant
- Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
- Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers
- How the coronavirus infects cells — and why Delta is so dangerous
- Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas
- Epsilon: SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
- Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant
- Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada, February to June, 2021
- SARS-CoV-2 variants of concern and variants under investigation in England (June 25)
- S-Gene Target Failure as a Marker of Variant B.1.1.7 Among SARS-CoV-2 Isolates in the Greater Toronto Area, December 2020 to March 2021
- Identification of a novel lineage bat SARS-related coronaviruses that use bat ACE2 receptor
- Timing the SARS-CoV-2 index case in Hubei province
- Risk of death from B117 variant of concern
- B117 in long term care facilities, England
- Risk of mortality for B117
- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
- Genetic epidemiology of SARS CoV 2 in South America
- Transmissbility of B117
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
- Increased viral load with B117
- NERVTAG report on increased severity and risk of death with UK variant
- Explainer on variants of concern
- Increased risk of death with B117
- Evolution of mutations in immunocompromised host treated with convalescent plasma
- Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies
- Rapid genetic evolution in an immunocompromised host
- The VUI-202012/01 (B117) mutation in the UK
- Evolutionary origin of SARS CoV 2
- Genetic epidemiology in Maryland
- Interpretation of positive PCR after recovery
- D614G mutation increases infectivity of SARS-CoV-2
- Cryptic transmission in Washington state
- The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity
- Korber at al. The G vs D strain and explanation by Trevor Bedford
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet
- Nextstrain.org from The Bedford Lab provides a continually updated phylogenetic tree
- Phylogenetic analysis of SARS-CoV-2
- On the origin and continuing evolution of SARS-CoV-2. National Science Review,
- The proximal origin of SARS-CoV-2. Nature Medicine
- The proximal origin of SARS CoV 2
- Synthetic SARS CoV 2
-
- Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
- Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave
- Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark
- Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose
- Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
- Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland
- Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
- SARS-CoV-2 Omicron Variant Infection in 10 Persons Within 90 Days of Previous SARS-CoV-2 Delta Variant Infection — Four States, October 2021–January 2022
- Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation
- Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
- COVID-19 vaccine breakthrough infections
- Omicron data from Discovery South Africa
- Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
- Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant
- Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort. - Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021
- Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections (long COVID)
- Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021
- Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study
Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021 separator - Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study
- The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission
- Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections
in the UK - COVID-19 Vaccine Breakthrough Infections in Veterans Health Administration
- Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce
- The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccine
- Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
- Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker
- Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
- New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
- Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021
- A grim warning from Israel: Vaccination blunts, but does not defeat Delta
- Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections
- Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
- Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study
- Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
- Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
- CDC slide presentation 29/7/21
- SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough
- Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas
- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers (Alpha)
- Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021
- Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
-
- A Critical Analysis of the Evidence for the SARS-CoV-2 Origin Hypotheses
The impact of the World Military Games on the COVID-19 pandemic - Covid-19: Early Cases and Disease Spread
- Surveillance of SARS-CoV-2 at the Huanan Seafood Market
- Perspectives: Back to Science in Searching for SARS-CoV-2 Origins
- What is a furin cleavage site, why is it important, and how might this have arisen in SARS-CoV-2?
Genetic evidence of susceptible wildlife in SARS-CoV-2 positive samples at the Huanan Wholesale Seafood Market, Wuhan: Analysis and interpretation of data released by the Chinese Center for Disease Control - Discovery of a novel merbecovirus DNA clone contaminating agricultural rice sequencing datasets from Wuhan, China and commentary about this paper
- Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019
- Structural basis for mouse receptor recognition by SARSCoV2 Omicron variant
- Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019
- Lethal Pneumonia Cases in Mojiang Miners (2012) and the Mineshaft Could Provide Important Clues to the Origin of SARS-CoV-2
- SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant
- How COVID-19’s origins were obscured, by the East and the West
- The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic
- The costs and benefits of primary prevention of zoonotic pandemics
- The Contested Origin of SARS-CoV-2
- Timing the SARS-CoV-2 index case in Hubei province
- Dissecting the early COVID-19 cases in Wuhan
- Closest known relatives of virus behind COVID-19 found in Laos
- The presence of SARS-CoV-2 RNA in human sewage in Santa Catarina, Brazil, November 2019
- The shifting sands of ‘gain-of-function’ research
An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2 - SARS-CoV-2 spike and its adaptable furin cleavage site
- Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy
- Evidence of SARS-CoV-2 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019
- Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020
- Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based “CONSTANCES” cohort
- Clues to Covid-19’s Origins Include Anonymous Skin Sample in Italy
- Sentinel surveillance of SARS-CoV-2 in wastewater anticipates the occurrence of COVID-19 cases Spain
- WHO report on origins
- Recovery of deleted deep sequencing data sheds more light on the early Wuhan SARS-CoV-2 epidemic
- In silico comparison of SARS‑CoV‑2 spike protein‑ACE2 binding affinities across species and implications for virus origin
- Investigate the origins of COVID-19
- Unexpected novel Merbecovirus discoveries in agricultural sequencing datasets from Wuhan, China
- Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic
- The genetic structure of SARS-CoV-2 does not rule out a laboratory origin
- The proximal origin of SARS-CoV-2
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- A Critical Analysis of the Evidence for the SARS-CoV-2 Origin Hypotheses
-
- A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
- Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
- Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases
- Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants
- Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection (vs treated with Pax)
- Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19
- Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
- Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
- Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro\
- Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease
- Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data
- Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
- Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis - Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
- Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection
- Multiple BCG vaccinations for prevention of COVID-19 and other infectious diseases in Type 1 diabetes
- Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial and updated meta-analysis
- SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial
- Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
- Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
- New COVID-19 nasal spray outperforms current antibody treatments in mice
- Oral Nirmatrelvir (Paxlovid) for High-Risk, Nonhospitalized Adults with Covid-19
- Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization A Systematic Review and Meta-analysis
- Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial
- Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials
- Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
- A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
- Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19
- Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
- Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19
- Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
- Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19
- Molnupiravir: Is It Time to Move In or Move Out?
- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
- The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19 - Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for preventing and reducing severe illness
- Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports
- Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
- Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia
The COVID STEROID 2 Randomized Trial - Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
- The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 - Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
- Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial
- Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia
- Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis
- Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 InfectionA Randomized Clinical Trial
- Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
- Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
- Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
- Convalescent plasma RECOVERY trial
- Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care UnitThe INSPIRATION Randomized Clinical Trial
- Inhaled steroids for mild COVID-19
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- IL6 antagonists (REMAP-CAP trial)
- Recovery trial - dexamethasone
- Meta-analysis of convalescent plasma
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- RCT of Vitamin D
- WHO Solidarity trial
- Tocilizumab
- RCT of convalescent plasma
- RCT of Monoclonal antibody LYCoV555
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- Aspirin for COVID-19
- Vitamin D pilot RCT
- Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019The GRECCO-19 Randomized Clinical Trial
- No benefit of HCQ
- WHO solidarity trial
- Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel
- Heparin - role of heparan sulfate in spike protein binding
- RCT of Remdesivir (JAMA)
- Colchicine as a treatment (JAMA)
- Low dose steroids
- Hydroxychloroquine and azithromycin
- Neutralising antibody in an animal model (Science)
- Convalescent plasma (RCT) (JAMA)
- Recombinant, soluble ACE2
- No efficacy of HCQ as prophylaxis for contacts (NEJM)
- No difference between 5 or 10 days of remdesevir
- Remdesivir - shorter time to recovery (NEJM)
- Hydroxychloroquine and chloroquine associated with increased mortality. - the veracity of the data in this study has been questioned and a letter signed by hundreds of scientists sent to Lancet
- Expression of concern from Lancet about HCQ study above
- Ivermectin shows invitro activity against SARS-CoV-2
- COVID-19. hyperglycaemia and hydroxychloroquine
- Lopinavir-ritonavir with and without IFNB
- Anakinra (Lancet Rheumatology)
- Remdesivir RCT (Lancet)
- Anti-HCV, Nucleotide Inhibitors, Repurposing Against COVID-19
- Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta Against MERS-CoV."
- The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)." Nature Reviews
- Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19)
- Is ibuprofen safe for people with COVID-19?
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- remdesivir and chloroquine
- No evidence of improved viral clearance on hydroxychloroquine and azithromycin
- Compassionate use of remdesivir (NEJM)
- RCT of hydroxychloroquine
- Should ACE inhibitors be continued?
- ACEI/ARB not associated with mortality
- Convalescent serum
- ACEI not associated with in-hospital mortality (NEJM)
-
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans
SARS-CoV-2 infection history and antibody response to three COVID-19 mRNA vaccine doses
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
- Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
- Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study
- Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States
- Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose
- IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination
- A Bivalent Omicron-Containing Booster Vaccine against Covid-19
- Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection
- The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2
- Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021
- Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
- Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021
- SARS-CoV-2 Infection in Patients with a History of VITT
- Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
- Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
- Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
- Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
- Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
- Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
- SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals
- Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
- Population Immunity and Covid-19 Severity with Omicron Variant in South Africa
- Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
- Herd immunity by infection does not work - SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
- Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
- Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation
- mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
- Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021
- UK COVID-19 vaccine surveillance report March 24 2022 - data on VE against Omicron by 1, 2, 3 doses
- Infection no better than Vaccine in protecting: Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
- Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
- Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
- Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants - Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
- Analysis of COVID-19 Risk Following a Ring Vaccination Intervention to Address SARS-CoV-2 Alpha Variant Transmission in Montreal, Canada
- Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
- Homologous and Heterologous Covid-19 Booster Vaccinations
- Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination - BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant - Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
- SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
- Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
- Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
- Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
- SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India
- Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older
- Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
- Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination
- Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
- Incidence and Estimated Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Among Persons Tested in US Retail Locations, May 1 to August 7, 2021
- Analysis of Vaccine Effectiveness Against COVID-19 and the Emergence of Delta and Other Variants of Concern in Utah
- Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study
- Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
- SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity (Walter Reed pan-COV vaccine)
- A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
- Studies of Walter Reed SfPN vaccine
- The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant
- Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
- Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar - Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
- Protection against Covid-19 by BNT162b2 Booster across Age Groups
BNT162b2 Vaccine Booster and Mortality Due to Covid-19 - Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
- Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant
- Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older
- Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults
- Efficacy of 3rd dose Pfizer slides (ACIP)
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity - Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (UK)
Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021 separator commenting unavailable - A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
- Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country
- Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy
- Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021
- Guaranteed Financial Incentives for COVID-19 Vaccination A Pilot Program in North Carolina
- Waning Immunity after the BNT162b2 Vaccine in Israel
- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
- Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
- Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
- BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant
- FDA presentation on boosters - data from Israel
- Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
- Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19
- COVID-19 Vaccine Effectiveness by Product and Timing in New York State
- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19 - Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
- Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- Myocarditis and Pericarditis After Vaccination for COVID-19
- Insights in ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
- Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
- Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021
- Effect of Vaccination on Transmission of SARS-CoV-2
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy - Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
- Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study
- Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
- Surveillance for Adverse Events After COVID-19 mRNA Vaccination
- Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine
- Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
- Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study
- Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients
- BNT162b2 vaccine booster dose protection: A nationwide study from Israel
- COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years – COVID2 NET, 13 states, January 1 – July 24, 2021
- Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
- Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study
- Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
- Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
- A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- SARS-CoV-2 variants: levels of neutralisation required for protective immunity
- Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease
- Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
- Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children
- Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
- Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
- Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
- Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis
- Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021
- Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021
- Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021
- SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine
- Antibody Evolution after SARS-CoV-2 mRNA Vaccination
- A pan coronavirus vaccine? Broad betacoronavirus neutralization by a stem helix–specific human antibody
- Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
- Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
- Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis
- Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine (waning VE)
- Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
- Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
- Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021
- Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
- Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
- Mix-and-match COVID vaccines trigger potent immune response
- Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile (Sinovac)
- Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
- A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination
- Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines (CDC authors)
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
- Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
- Novavax Phase 3 RCT (NEJM)
- Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial
- Vaccine- induced Immune Thrombocytopenia and Thrombosis (VITT)
- Thrombosis After Vaccination With Messenger RNA–1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome?
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
- Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine
- SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
- Effect of Vaccination on Household Transmission of SARS-CoV-2 in England
- SARS-CoV-2 Variants and Vaccines
- Myocarditis following COVID-19 mRNA vaccination
- SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
- Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
- Effectiveness of AZ and Pfizer against Delta (hospitalisation)
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
- Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia
- Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsA Randomized Clinical Trial (Sinopharm)
- COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
- Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents
- Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
- Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
- Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
- Vaccine-Induced Covid-19 Mimicry” Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents List of authors.
- Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and Quadrivalent Seasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
- Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
- SARS-CoV-2 Antibody Response in Persons with Past Natural Infection
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia
- Heterologous vaccine schedules
- Infections, Hospitalizations, and Deaths Averted Via Direct Effects of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Vaccination Campaign, Israel
- The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India 2 Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal 3 Antibodies
- Adverse events following Pfizer and AZ in the UK
- Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
- Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
- BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
- Real world effectiveness of JnJ
- Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)
- Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households
- Impact of vaccination on household transmission of SARS-COV-2 in England
- Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
- Mucosal immunity after vaccination
- Pfizer vaccine effectiveness agains B117 and B1351
- Combination Respiratory Vaccine Containing Recombinant SARS-CoV-2 Spike and Quadrivalent Seasonal Influenza Hemagglutinin Nanoparticles with Matrix-M Adjuvant
- COVID-19 dynamics after a national immunization program in Israel
- Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
- US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
- Immunogenicity of BNT162b2 in cancer patients
- Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
- Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
- COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- Successful treatment of VITT
- mrna vaccines in pregnant women
- Post-vaccination outbreak in aged care
- Phase 3 trial JnJ
- Herpes zoster after Pfizer COVID-19 vaccine
- COVID-19 dynamics after a national immunization program in Israel
- Pathology of VITT
- VITT following J&J
- Phase 3 trial Sinovac
- Anti-SARS-CoV-2 Spike Protein and Anti-Platelet Factor 4 Antibody Responses Induced by COVID-19 Disease and ChAdOx1 nCov-19 vaccination
- AZ and VIPIT (NEJM)
- Immune response after infection and 1 dose vaccine
- Novavax, Moderna neutralisation against variants of concern
- EMA statement on AZ vaccine and VIPIT
- Adverse events following mRNA vaccines
- Duration of immunity, Moderna
- VIPIT - British Haematologists guidelines
- VIPIT guidelines Canada
- AZ- associated Vaccine induced prothrombotic immune thrombocytopena - list of case reports
- A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination
- Pfizer press release - trial of children 12-16
- VE of AZ against B117
- Herd immunity, Israel?
- Effectiveness of mRNA vaccines against all infection in US
- Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
- European Medicines Agency statement on AZ and CVT
- AZ trial in the US - press release
- Neutralising antibodies after Pfizer vaccine
- mRNA vaccine explainer
- Moderna vaccine activity against variants of concern
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (NEJM)
- The rise of SARS-CoV-2 variant B.1.1.7 in Israel intensifies the role of surveillance and vaccination in elderly
- Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study
- Immunogenicity of Ad26 COVID-19 vaccine (JnJ)
- Antibody response to Pfizer in seropositive people
- Neutralizing Activity of BNT162b2-Elicited Serum
- Delayed local reactions to mRNA vaccines
- Immunogenicity of single dose Pfizer and Moderna vaccines after natural infection
- Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
- Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
- Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People
- Impact of vaccinating older adults
- Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)
- COVID vaccines in pregnant women
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting - Israel
- Janssen vaccine FDA submission
- Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People
- Bells palsy and mRNA vaccines
- First real-world UK data shows Pfizer-BioNTech vaccine provides high levels of protection from the first dose
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
- Moderna vaccine response to variants
- FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- Neutralisation against variants of concern - Pfizer
- Neutralisation against variants of concern - Moderna
- Reduced efficacy of AZ vaccine in South Africa
- Impact of vaccination in Israel
- Reduced viral load after vaccination with Pfizer (Israel)
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
- Sputnik vaccine interim phase 3
- Commentary on Sputnik and other Ad vectored vaccines
- Sinopharm vaccines neutralising ability against South African variant
- Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
- J&J press release
- Novavax press release - reduced efficacy against mutants
- Novavax preclinical (animal) study
- Bharat Biotech Phase 1
- Moderna press release on UK, South African variants of concern
- Sanofi and GSK phase 1 trial
- J&J Phase 1-2 trial
- Sinovac phase 1/2
- Adenoviral vectors for vaccines explained
- Mandating COVID vaccines - legal and ethical considerations
- Moderna RCT
- Herd immunity through vaccination
- mRNA vaccines explained
- Pfizer phase 3 trial
- Astra Zeneca Phase 3 trial
- Astra Zeneca Phase 2/3 RCT
- Requirements for herd immunity with a vaccine
- Prospects for a safe vaccine
- Pfizer vaccine phase 1 NEJM
- Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
- Sinovac CORONAVAC phase 1/2 RCT
- The problems with adenovirus vectors explained
- Influenza vaccine and COVID19
- WHO summary of vaccines in development
- Russian adenovirus 5 and 6 prime boost vaccine
- Critique of Russian data
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (Novavax/UQ)
- List of authors.Attitudes to vaccines
- Antibody dependent enhancement
- Whole inactivated vaccine shows good immunogenicity and safety
- Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
- Moderna vaccine Phase 1 trial
- First in humans phase 1 trial of adenovirus 5 vectored COVID19 vaccine
- No association between childhood BCG and COVID-19 (JAMA)
- Eight different approaches to COVID19 vaccines explained
- Overview of different vaccine approaches by Sinobiologicals
- Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
- BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)
- Treatment for severe acute respiratory distress syndrome from COVID-19
- Vaccine development landscape for COVID-19
- Influenza vaccine and viral interference with coronaviruses
- The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement
-
- A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
- Delayed production of neutralizing antibodies correlates with fatal COVID-19
- Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset
- Antibody responses and symptoms
- Reinfection in Manaus, Brazil
- Antibody dependent enhancement explained
- Duration of immunity after infection
- Cross reaction with human seasonal coronavirus memory T cells
- Autoantibodies against IFN
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- Inhibition of IFN by SARS CoV 2
- Serological responses at 4 months after infection in Iceland
- Immune responses in older people
- SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection
- Deep immune profiling
- Pre-existing immunity
- Genomewide Association Study of Severe Covid-19 with Respiratory Failure
- Cross-reactive S-reactive CD4 cells in SARS-CoV-2 negative people
-
- Detection of viable SARS-CoV-2 in retrospective analysis of aerosol samples collected from hospital rooms of patients with COVID-19
Outbreak of SARS-CoV-2 Omicron Infection in a Centralized Quarantine Location in Hangzhou, China - Monitoring SARS-CoV-2 in air and on surfaces and estimating infection risk in buildings and buses on a university campus
- Far-UVC (222 nm) efficiently inactivates an airborne pathogen in a room-sized chamber
- Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh
- Residential air-change rates: A critical review
- Spread of SARS-CoV-2 aerosols via two connected drainage stacks in a high-rise housing outbreak of COVID-19
- Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
- Can a toilet promote virus transmission? From a fluid dynamics perspective
- Practical Indicators for Risk of Airborne Transmission in Shared Indoor Environments and Their Application to COVID-19 Outbreaks
- Airborne Transmission of SARS-CoV-2 Delta Variant within Tightly Monitored Isolation Facility, New Zealand (Aotearoa)
- Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021
- Personal protective equipment does not sufficiently protect against virus aerosol unless combined with advanced air purification or ventilation techniques
- Respiratory Aerosol Emissions from Vocalization: Age and Sex Differences Are Explained by Volume and Exhaled CO2
- Airborne SARS-CoV-2 in home- and hospital environment investigated with a high-powered air sampler
- The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units
- Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building
- Poor ventilation worsens short-range airborne transmission of respiratory infection
- The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units
- Insufficient ventilation led to a probable long-range airborne transmission of SARS-CoV-2 on two buses
- Assessment of Aerosol Generating Events During the Nasopharyngeal Swabbing for SARS-CoV-2 Detection
- Airborne transmission of respiratory viruses
- The size and culturability of patient-generated SARS-CoV-2 aerosol
- Use of portable air cleaners to reduce aerosol transmission on a hospital coronavirus disease 2019 (COVID-19) ward
- https://science.sciencemag.org/content/372/6549/1439?utm_campaign=SciMag&utm_source=Social&utm_medium=TwitterViral Load of SARS-CoV-2 in Respiratory Aerosols Emitted by COVID-19 Patients while Breathing, Talking, and Singing
- Expiratory aerosol particle escape from surgical masks due to imperfect sealing
- Breathing, speaking, coughing or sneezing: What drives transmission of SARS-CoV-2?
- Probable airborne transmission of SARS-CoV-2 in a poorly ventilated restaurant
- Outdoor Airborne Transmission of Coronavirus Among Apartments in High-Density Cities
- Indoor Air Changes and Potential Implications for SARS-CoV-2 Transmission
- Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness
- Airborne transmission of SARS CoV 2 between ferrets
- Risk factors and on-site simulation of environmental transmission of SARS-CoV-2 in the largest wholesale market of Beijing, China
- Cold-chain food contamination as the possible origin of COVID-19 resurgence in Beijing
- Mechanistic transmission modeling of COVID-19 on the Diamond Princess cruise ship demonstrates the importance of aerosol transmission
- Particle sizes of infectious aerosols: implications for infection control
- Characterization of hospital airborne SARS-CoV-2
- Aerosol filtration efficiency of household materials for homemade face masks: Influence of material properties, particle size, particle electrical charge, face velocity, and leaks
- Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards
- SARS CoV 2 in the air inside a car
- Prof Don Milton lecture on aerosols
- Is wiping surfaces of any use?
- Detection of SARS-CoV-2 within the healthcare environment: a multicentre study conducted during the first wave of the COVID-19 outbreak in England
- Assessment of Air Contamination by SARS-CoV-2 in Hospital Settings
- Another building with transmission through air ducts
- Short range aerosols
- Aerosol generation during intubation, extubation and coughing
- Virus on banknotes and touch screens for weeks
- Effect of air purifiers in closed classrooms
- Airborne transmission of SARS CoV2
- Aerosol transmission in a choir practice
- Viable airborne SARS CoV 2 in the absence of aerosol generating procedures
- CDC list of disinfectants for SARS CoV 2
- Aerosol generation and a novel hood for COVID-19 patients
- Airborne transmission in aged care
- Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building
- Evidence of airborne transmission of SARS CoV2 including spread through a building
- Aerodynamics of SARS CoV 2 in a hospital in Wuhan
- Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event
- Quantitative assessment of the risk of airborne transmission of SARS-CoV-2 infection: prospective and retrospective applications
- Evidence of aerosol transmission
- Viable SARS CoV2 in air
- Airborne SARS-CoV-2 is Rapidly Inactivated by Simulated Sunlight
- Reducing transmission of SARS CoV 2
- Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission
- Study comparing original and modified WHO hand sanitizer formulation against SARS-CoV-2
- Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals (Nature)
- Comparative dynamic aerosol efficiencies of three emergent coronaviruses and the unusual persistence of SARS-CoV-2 in aerosol suspensions (from NIH, USAMRID, UTMB, Tulane)
- Aerosol transmission of SARSCoV2 - review
- Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient JAMA.
- 6
- Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. NEJM.
- Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents.
- SARS-CoV 2 found on surfaces in the Diamond Princess 17 days after passengers disembarked
- SARSCoV2 on banknotes, masks and other surfaces
- SARSCoV2 in wastewater in US
- SARS COV2 - environmental contamination, air vents, air samples and spread 4m from patient
- Widespread contamination and airborne transmission - University of Nebraska Medical Center
- Detection of Air and Surface Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Hospital Rooms of Infected Patients
- Aerodynamic Characteristics and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during COVID-19 Outbreak
- Re-use and decontamination on N95 respirators
- Persistence of aerosolised viable SARS-CoV2
- Disinfection methods for re-using single use PPE
- COVID-19 in air pollution particles
- National academies of science (NAS) Rapid Expert Consultation on SARS-CoV-2 Survival in Relation to Temperature and Humidity and Potential for Seasonality for the COVID-19 Pandemic (April 7, 2020) (2020)
- Other NAS rapid reviews
- Detection of viable SARS-CoV-2 in retrospective analysis of aerosol samples collected from hospital rooms of patients with COVID-19
-
- Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community
A Randomized Clinical Trial - Efficacy of Do-It-Yourself air filtration units in reducing exposure to simulated respiratory aerosols
- Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff
- Misrepresentation and Nonadherence Regarding COVID-19 Public Health Measures
- Impact of Age and Symptom Development on SARS-CoV-2 Transmission in Households With Children—Maryland, New York, and Utah, August 2020–October 2021
- A simple surgical mask modification to pass N95 respirator-equivalent fit testing standards during the COVID-19 pandemic
- Association of COVID-19 Infection With Wearing Glasses in a High-Prevalence Area in Denmark and Sweden
- Risk of SARS-CoV-2 Acquisition in Health Care Workers According to Cumulative Patient Exposure and Preferred Mask Type
- Examination of SARS-CoV-2 In-Class Transmission at a Large Urban University With Public Health Mandates Using Epidemiological and Genomic Methodology
- Far-UVC (222 nm) efficiently inactivates an airborne pathogen in a room-sized chamber
- Factors affecting adherence to non-pharmaceutical interventions for COVID-19 infections in the first year of the pandemic in the UK
- Rapid control of hospital-based SARS-CoV-2 Omicron clusters through daily testing and universal use of N95 respirators
- Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021
- N95 respirator and surgical mask effectiveness against respiratory viral illnesses in the healthcare setting: A systematic review and meta‐analysis
- An upper bound on one-to-one exposure to infectious human respiratory particles
- Automated Digital Notification of COVID-19 Diagnoses Through Text and Email Messaging — North Carolina, December 2020–January 2021
Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis - Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study
- Safe traveling in public transport amid COVID-19
- Effects of covid-19 pandemic on life expectancy and premature mortality in 2020: time series analysis in 37 countries
- Protective Behaviors Against COVID-19 by Individual Vaccination Status in 12 Countries During the Pandemic
- Assessment of Simulated Surveillance Testing and Quarantine in a SARS-CoV-2–Vaccinated Population of Students on a University Campus
- Contact tracing: digital health on the frontline
Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study - SARS-CoV-2 aerosol transmission in schools: the effectiveness of different interventions
- Ranking the effectiveness of worldwide COVID-19 government interventions (curfews among most effective)
- Laboratory Study of Physical Barrier Efficiency for Worker Protection against SARS-CoV-2 while Standing or Sitting
- Association of Simulated COVID-19 Policy Responses for Social Restrictions and Lockdowns With Health-Adjusted Life-Years and Costs in Victoria, Australia
- Close proximity risk assessment for SARS-CoV-2 infection
- Mask Mandates, On-Premises Dining, and COVID-19
- Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020
- Health and economic costs of early and delayed suppression and the unmitigated spread of COVID-19: The case of Australia
- Assessment of Day-7 Postexposure Testing of Asymptomatic Contacts of COVID-19 Patients to Evaluate Early Release from Quarantine — Vermont, May–November 2020
- Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020
- Prevention of SARS-CoV-2 transmission from international arrivals: Xiaotangshan Designated Hospital, China
- COVID-19 transmission in Hong Kong despite universal masking
- SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties
- Estimating and mitigating the risk of COVID-19 epidemic rebound associated with reopening of international borders in Vietnam: a modelling study
- Air cleaners for the COVID ward
- Testing mobile air purifiers in a school classroom: Reducing the airborne transmission risk for SARS-CoV-2
- Elastomeric vs N95 during resuscitation
- Effect of 3ft vs 6ft distancing in schools
- Assessment of Use and Fit of Face Masks Among Individuals in Public During the COVID-19 Pandemic in China
- Summary evidence for masks
- Quarantine and isolation for reducing transmission
- Evidence for masks against SARS CoV 2
- Social distancing impact
- Reducing transmission of SARS CoV 2
- Assessing the impact of coordinated COVID-19 exit strategies across Europe
- Universal masking in hospitals
- Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries
- Impact of lockdown in UK on health services
- Comparison of Estimated Rates of Coronavirus Disease 2019 (COVID-19) in Border Counties in Iowa Without a Stay-at-Home Order and Border Counties in Illinois With a Stay-at-Home Order
- Contact tracing efficacy
- Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China
- The effectiveness of full and partial travel bans against COVID-19 spread in Australia for travellers from China.
- Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts.
- The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak.
- Comparing nonpharmaceutical interventions for containing emerging epidemics
- Backcalculating the Incidence of Infection with COVID-19 on the Diamond Princess
- COVID-19 Outbreak on the Diamond Princess Cruise Ship: Estimating the Epidemic Potential and Effectiveness of Public Health Countermeasures.
- Quantifying the association between domestic travel and the exportation of novel coronavirus (2019-nCoV) cases from Wuhan, China in 2020: a correlational analysis
- Assessing the Impact of Reduced Travel on Exportation Dynamics of Novel Coronavirus Infection (COVID-19).
- Association between 2019-nCoV transmission and N95 respirator use.
- Transmission potential of the novel coronavirus (COVID-19) onboard the Diamond Princess Cruises ship, 2020
- Modelling the coronavirus disease (COVID-19) outbreak on the Diamond Princess ship using the public surveillance data from January 20 to February 20, 2020
- Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore — January 2–February 29, 2020. EID
- Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand
- Difference between no, moderate or extensive social distancing in US (Columbia University model)
- Non-pharmaceutical including universal face mask use measures for COVID-19 control in US
- Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community
-
- Association of University Student Gatherings With Community COVID-19 Infections Before and After the NCAA March Madness Tournament
- A high attack rate of 90% of SARS-CoV-2 Delta variant infections in crew personnel on a single navy ship
- Incidence of SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential Workers During a Prevaccination COVID-19 Surge in Arizona
- Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison
- Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study
- Avoiding COVID-19 Outbreaks in Carceral Settings
- Association Between Prison Crowding and COVID-19 Incidence Rates in Massachusetts Prisons, April 2020-January 2021
- SARS-CoV-2 outbreak in a long-term care facility after vaccination with BNT162b2
- Cruise ship outbreaks - Australia as a case study
- A nightclub outbreak in Germany
- Residential context and COVID-19 mortality among adults aged 70 years and older in Stockholm: a population-based, observational study using individual-level data
- Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 During Long Flight
- Home outbreaks >50% of all outbreaks. Superspreading <2%
- An outbreak on a bus suggestive of airborne transmission
- An outbreak on an aircraft
- Asymptomatic transmission on an aircraft linked to toilets
- Long range transmission in a meat packing plant
- Mass testing in US prisons
- COVID-19 in US prisons
- OUtbreak on a navy ship (60% attack rate)
- Systematic review of aged care outbreaks
- Managed outbreak in Seattle assisted living facility
- OUtbreak in aged care facility in Washington State
- Church group outbreak in Arkansas
- Serial testing in a veterans facility, US
- Outbreak in a choir in Washington State
- COVID-19 in US prisons
- Outbreak in homeless shelters, US
- COVID-19 in meat processing plants, US
-
- Risk of SARS-CoV-2 Acquisition in Health Care Workers According to Cumulative Patient Exposure and Preferred Mask Type
- Effectiveness of Elastomeric Half-Mask Respirators vs N95 Filtering Facepiece Respirators During Simulated Resuscitation
- Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers
- Why did so few healthcare workers in China get COVID-19 infection
- The effect of respiratory activity, ventilatory therapy and facemasks on total aerosol emissions
- Seroprevalence in health workers in UK
- COVID-19 in HCW
- Seroprevalence in US HCW
- Intubation does not generate as much aerosol as coughing
- Community Health Workers and Covid-19 — Addressing Social Determinants of Health in Times of Crisis and Beyond
- zero HCW infections in Taiwan
- Origin of aerosol generating procedures
- Study of HCW in the Netherlands
- Risk in HCW in UK
- Low risk of infection of HCW in Taiwan
- Study of HCW PPE and infection risk in China
- Masks, N95, eye protection and physical distancing - WHO commissioned meta-analysis
- Commentary on WHO meta-analysis
- Risk of infection in HCW (Annals)
- Deaths of health workers in China (NEJM)
- Supporting the Health Care Workforce During the COVID-19 Global Epidemic. JAMA.
- Asymptomatic infection in health workers in the Netherlands
- One in 5 HCW infected with COVID19 in UK
- Cloth masks not suitable for health workers
- Effectiveness of N95 respirators in protecting HCWs from COVID-19
- Barrier intubation method
- Droplet or airborne precautions?
- Risk of transmission in primary care
-
- Lifting Universal Masking in Schools — Covid-19 Incidence among Students and Staff
- Effect of Wearing a Face Mask on Hand-to-Face Contact by Children in a Simulated School Environment
- A simple surgical mask modification to pass N95 respirator-equivalent fit testing standards during the COVID-19 pandemic
- Risk of SARS-CoV-2 Acquisition in Health Care Workers According to Cumulative Patient Exposure and Preferred Mask Type
- Fit-Tested N95 Masks Combined With Portable High-Efficiency Particulate Air Filtration Can Protect Against High Aerosolized Viral Loads Over Prolonged Periods at Close Range
- Examination of SARS-CoV-2 In-Class Transmission at a Large Urban University With Public Health Mandates Using Epidemiological and Genomic Methodology
- Fit-Tested N95 Masks Combined With Portable High-Efficiency Particulate Air Filtration Can Protect Against High Aerosolized Viral Loads Over Prolonged Periods at Close Range
- Mask wearing in community settings reduces SARS-CoV-2 transmission
- Perimeter leakage of face masks and its effect on the mask's efficacy
- An upper bound on one-to-one exposure to infectious human respiratory particles
- Factors affecting adherence to non-pharmaceutical interventions for COVID-19 infections in the first year of the pandemic in the UK
- Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh
- Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021
- N95 respirator and surgical mask effectiveness against respiratory viral illnesses in the healthcare setting: A systematic review and meta‐analysis
- Randomized crossover study comparing quantitative fit tests between Trident™ and 3M™ Aura™ N95/P2 respirators
- Case-Control Study of Use of Personal Protective Measures and Risk for SARS-CoV 2 Infection, Thailand
- The role of mask mandates, stay at home orders and school closure in curbing the COVID-19 pandemic prior to vaccination
- Effectiveness of personal protective health behaviour against COVID-19
- Relationship Between COVID-19 Infection and Risk Perception, Knowledge, Attitude, and Four Nonpharmaceutical Interventions During the Late Period of the COVID-19 Epidemic in China: Online Cross-Sectional Survey of 8158 Adults
- A feasible route for the design and manufacture of customised respiratory protection through digital facial capture
- What can masks do? Part 1: The science behind COVID-19 protection
- Face mask fit modifications that improve source control performance
- Efficacy of Portable Air Cleaners and Masking for Reducing Indoor Exposure to Simulated Exhaled SARS-CoV-2 Aerosols — United States, 2021
- Infectious SARS-CoV-2 in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection
- Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic
- The Impact of Community Masking on COVID-19: A Cluster-Randomized Trial in Bangladesh
- Graphene- and Nanoparticle-Embedded Antimicrobial and Biocompatible Cotton/Silk Fabrics for Protective Clothing
- American Academy of Pediatrics guidance on masks in schools
- Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2
- Face masks effectively limit the probability of SARS-CoV-2 transmission
- Designing a a high performance cloth mask (video)
- Experimental Evidence for the Optimal Design of a High-Performing Cloth Mask
- Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools — Georgia, November 16–December 11, 2020
- Face masks effectively limit the probability of SARS-CoV-2 transmission
- The Impact of Universal Mask Use on SARS-COV-2 in Victoria, Australia on the Epidemic Trajectory of COVID-19
- Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2
- Transmission of SARS-CoV-2 from asymptomatic and presymptomatic individuals in healthcare settings despite medical masks and eye protection
- Review of evidence on masks and N95s
- Re-use of FFPs
- Quantitative Protection Factors for Common Masks and Face Coverings
- Effectiveness of eye protection
- Droplet blocking by masks
- Face masks considerably reduce COVID-19 cases in Germany
- Effectiveness of mask mandates
- Danish mask RCT
- Face shields do not work
- Trends in COVID-19 Incidence After Implementation of Mitigation Measures (masks) — Arizona, January 22–August 7, 2020
- Evidence of effectiveness of community masks - Canada
- Contamination and washing of cloth masks
- Masks for all?
- Washing of cloth masks
- Social and behavioral consequences of mask policies during the COVID-19 pandemic
- Evidence for community mask use
- Mandating masks works - data from Germany
- A video case study of surgical vs cloth masks
- Only those wearing a face-shield got infected
- The need of health policy perspective to protect Healthcare Workers during COVID-19 pandemic. A GRADE rapid review on the N95 respirators effectiveness
- Coronavirus data from 4 RCTs
- Gamma irradiation degrades N95 respirators
- Clinical trials and other research on face masks from the MacIntyre research group
- Our latest systematic review on masks for HCW, community and sick patients
- N95 and COVID19 (from China)
- Aerosol filtration of common fabrics
- Use of nylon stockings over various masks
- Principles for design of cloth masks
- Testing of filtration of different DIY fabrics
- A simple respiratory mask
- Aerosol filtration of cotton and silk materials
- Filtration of cloth masks
-
- Access to intensive care in 14 European countries: a spatial analysis of intensive care need and capacity in the light of COVID-19
- The Risk of SARS-CoV-2 Transmission from Patients with Undiagnosed Covid-19 to Roommates in a Large Academic Medical Center
- Seroprevalence in outpatients in Virgina
- Nosocomial transmission of SARS-CoV-2
- COVID-19 and Italy: what next?
- Quarantine in Italy
- ICU beds in Australia
- Novel contact tracing using digital technology
- Oxford University government response tracker
- LSTMH Hospital bed surge capacity tool
- Health systems India
- Screening of all pregnant women attending an antenatal service in NY find 13% infected
- HOTEL QUARANTINE BREACHES, Australia
-
COVID-19 and Excess All-Cause Mortality in the US and 20 Comparison Countries, June 2021-March 2022
Employment in Office-Based and Intensive Behavioral Health Settings in the US, 2016-2021
Evaluation of science advice during the COVID-19 pandemic in Sweden
“The Sombre Aspect of the Entire Landscape” — Epidemiology and the Faroe Islands
-
- Actuaries Institute’s COVID-19 Mortality Working Group’s latest analysis of excess deaths
- Epiwatch - rapid epidemic intelligence
- View-Hub (vaccine effectiveness and other data)
- COVID hazard index
- UNSW Time Series Modelling global dashboard
- ESRI ARC GIS Australia COVID-19 DASHBOARD
- WHO dashboard
- Johns Hopkins KAP COVID (social and behavioural data)
- CovSPECTRUM (GISAID genetic sequencing data by country including variants)
- Imperial College KAP COVID
- Carnegie Mellon COVIDCast (US data)
- "Policy Tracker" Launched by the IMF March 25, summarizes the key economic responses governments are taking to limit the human and economic impact of the COVID-19 pandemic as of March 24, 2020.
- The Oxford COVID-19 Government Response Tracker was launched on March 24 and counts data from 73 countries so far, including China, South Korea, Italy, UK and USA. T
- PEW Research center